Udvalget for Veterinærlægemidler (CVMP) konkluderede, at fordelene ved Equilis Prequenza er større end risiciene til immunisering af heste, der er seks måneder gamle eller derover, mod hesteinfluenza for at reducere de kliniske symptomer og virusudskillelsen efter infektion.
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Equilis Prequenza exceeded the risks for the immunisation of horses from six months of age against equine influenza to reduce clinical signs and virus excretion after infection.